Hikma Pharmaceuticals PLC

LSE:HIK Rapporto sulle azioni

Cap. di mercato: UK£4.2b

Hikma Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Hikma Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 12.8% e 3.8% all'anno. Si prevede che l'EPS crescerà di 15.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 18.1% in 3 anni.

Informazioni chiave

12.8%

Tasso di crescita degli utili

15.9%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili19.3%
Tasso di crescita dei ricavi3.8%
Rendimento futuro del capitale proprio18.1%
Copertura analitica

Good

Ultimo aggiornamento18 Nov 2024

Aggiornamenti recenti sulla crescita futura

Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 11
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark

Nov 11
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Oct 24
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 11
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 01
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate

Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?

Apr 24
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Apr 02
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Feb 25
Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Dec 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Dec 12
An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Sep 19
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Sep 01
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Jun 21
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Jun 02
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Mar 14
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Feb 21
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Sep 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 24
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Jun 06
These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Feb 26
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Dec 01
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Nov 11
Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Sep 02
Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Aug 09
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

May 21
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

May 03
Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

Apr 16
It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Apr 13
How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Mar 14
Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 28
Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Previsioni di crescita degli utili e dei ricavi

LSE:HIK - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20263,3205235428178
12/31/20253,1774795177758
12/31/20243,0394433525528
6/30/20243,017285379584N/A
3/31/20242,946238392596N/A
12/31/20232,875190404608N/A
9/30/20232,803168389596N/A
6/30/20232,731146373583N/A
3/31/20232,624167344557N/A
12/31/20222,517188314530N/A
9/30/20222,534267325557N/A
6/30/20222,550346335583N/A
3/31/20222,552384372611N/A
12/31/20212,553421409638N/A
9/30/20212,489444294517N/A
6/30/20212,425467179396N/A
3/31/20212,383449210430N/A
12/31/20202,341431240464N/A
9/30/20202,317472306521N/A
6/30/20202,292513372577N/A
3/31/20202,250500329525N/A
12/31/20192,207486286472N/A
9/30/20192,173424283452N/A
6/30/20192,138361279432N/A
3/31/20192,104322285431N/A
12/31/20182,070282291430N/A
9/30/20182,045-262275417N/A
6/30/20182,020-806259403N/A
3/31/20181,978-824N/A423N/A
12/31/20171,936-843N/A443N/A
9/30/20171,950-338N/A431N/A
6/30/20171,963166N/A419N/A
3/31/20171,957161N/A356N/A
12/31/20161,950155N/A293N/A
9/30/20161,782166N/A317N/A
6/30/20161,613176N/A340N/A
3/31/20161,527214N/A353N/A
12/31/20151,440252N/A366N/A
9/30/20151,450248N/A358N/A
6/30/20151,460243N/A350N/A
3/31/20151,475261N/A388N/A
12/31/20141,489278N/A425N/A
9/30/20141,477293N/A413N/A
6/30/20141,465308N/A401N/A
3/31/20141,415260N/A369N/A
12/31/20131,365212N/A337N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di HIK ( 12.8% all'anno) è superiore al tasso di risparmio ( 2.1% ).

Guadagni vs Mercato: Si prevede che gli utili di HIK ( 12.8% all'anno) cresceranno più lentamente rispetto al mercato UK ( 14.6% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di HIK cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di HIK ( 3.8% all'anno) crescerà più rapidamente del mercato UK ( 3.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di HIK ( 3.8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di HIK sarà basso tra 3 anni ( 18.1 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y